Skip to content

AYALA PHARMACEUTICALS, INC.: 10-K filed 2012-01-26

What AYALA PHARMACEUTICALS, INC. reported in its annual report filed 2012-01-26 (fiscal FY 2011): 33 published measures, 101 facts as tagged in accession 0001144204-12-004201.

This filing

Form
10-K (annual report)
Filed
2012-01-26
Fiscal period
fiscal FY 2011
Accession
0001144204-12-004201 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYALA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-10-315,640,562USD
At 2010-10-312,875,186USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-10-3117,920,275USD
At 2010-10-3117,677,817USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-10-31-12,279,713USD
At 2010-10-31-14,802,631USD
At 2009-10-31-15,733,328USD
At 2008-10-31-839,311USD
At 2007-10-314,267,979USD
At 2006-10-31-3,707,141USD
At 2005-10-311,751,575USD
At 2004-10-31-1,339,496USD
At 2003-12-31-806,735USD
At 2002-12-3178,557USD
At 2002-02-280USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-8,115,740USD365
2002-03-01 to 2011-10-31-35,487,856USD3532
2009-11-01 to 2010-10-31-10,812,200USD365
2008-11-01 to 2009-10-31929,244USD365
2007-11-01 to 2008-10-31-5,416,418USD366
2006-11-01 to 2007-10-31-2,454,453USD365
2005-11-01 to 2006-10-31-6,197,744USD365
2004-11-01 to 2005-10-31-1,805,789USD365
2004-01-01 to 2004-10-31-538,076USD305
2003-01-01 to 2003-12-31-909,745USD365
2002-03-01 to 2002-12-31-166,936USD306

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-8,942,842USD365
2002-03-01 to 2011-10-31-29,665,759USD3532
2009-11-01 to 2010-10-31-6,423,940USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2010-11-01 to 2011-10-310USD365
2002-03-01 to 2011-10-31150,093USD3532
2009-11-01 to 2010-10-3112,436USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2010-11-01 to 2011-10-3110,227,357USD365
2002-03-01 to 2011-10-3133,873,070USD3532
2009-11-01 to 2010-10-316,739,708USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-296,358USD365
2002-03-01 to 2011-10-31-3,110,773USD3532
2009-11-01 to 2010-10-31-867,209USD365

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2010-11-01 to 2011-10-31222,918,519shares365
2009-11-01 to 2010-10-31150,928,808shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2010-11-01 to 2011-10-31222,918,519shares365
2009-11-01 to 2010-10-31150,928,808shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-0.04USD/shares365
2009-11-01 to 2010-10-31-0.07USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-0.04USD/shares365
2009-11-01 to 2010-10-31-0.07USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-379,472USD365
2002-03-01 to 2011-10-31-1,580,473USD3532
2009-11-01 to 2010-10-31-278,978USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-10-310USD
At 2010-10-3128,406USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2010-11-01 to 2011-10-31795,226USD365
2002-03-01 to 2011-10-313,800,645USD3532
2009-11-01 to 2010-10-31570,664USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-13,018,836USD365
2002-03-01 to 2011-10-31-42,473,230USD3532
2009-11-01 to 2010-10-31-7,926,015USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-10-311,614,021USD
At 2010-10-31391,371USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2010-11-01 to 2011-10-314,698,983USD365
2002-03-01 to 2011-10-3110,449,337USD3532
2009-11-01 to 2010-10-313,814,863USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-10-3110,895,961USD
At 2010-10-314,671,623USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-10-312,420,260USD
At 2010-10-312,586,008USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2010-11-01 to 2011-10-3113,018,836USD365
2002-03-01 to 2011-10-3144,336,573USD3532
2009-11-01 to 2010-10-318,434,496USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2010-11-01 to 2011-10-318,078,901USD365
2002-03-01 to 2011-10-3123,156,740USD3532
2009-11-01 to 2010-10-314,904,298USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-10-31250,173,570shares
At 2010-10-31198,100,817shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2011-10-312,256,852USD
At 2010-10-312,125,991USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-10-31323,738USD
At 2010-10-3196,096USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-10-312,976,334USD
At 2010-10-31647,125USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-9,654,426USD365
2002-03-01 to 2011-10-31-37,070,426USD3532
2009-11-01 to 2010-10-31-10,812,200USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2010-11-01 to 2011-10-314,939,935USD365
2002-03-01 to 2011-10-3121,179,833USD3532
2009-11-01 to 2010-10-313,530,198USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2010-11-01 to 2011-10-3128,406USD365
2002-03-01 to 2011-10-31195,672USD3532
2009-11-01 to 2010-10-3138,528USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2010-11-01 to 2011-10-31132,288USD365
2002-03-01 to 2011-10-31594,640USD3532
2009-11-01 to 2010-10-31100,420USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2010-11-01 to 2011-10-31-296,358USD365
2002-03-01 to 2011-10-31-2,915,740USD3532
2009-11-01 to 2010-10-31-854,773USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2010-11-01 to 2011-10-310USD365
2002-03-01 to 2011-10-3111,988,230USD3532
2009-11-01 to 2010-10-310USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2010-11-01 to 2011-10-31739,536USD365
2002-03-01 to 2011-10-313,906,728USD3532
2009-11-01 to 2010-10-31388,924USD365

Inspect the source

Entity
AYALA PHARMACEUTICALS, INC. / CIK 0001100397
Captured
SEC response SHA-256
c79571e45bf72206000628dd6d16cc0b78424a189c2c21675f51fe12cd89a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001100397.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))